Integrated Report 2018
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Akita University General Information Bulletin 2015
Akita University Outline | Akita 2015 Edition | GENERAL INFORMATION BULLETIN 2015 GENERAL INFORMATION University 2015 Edition Outline GENERAL INFORMATION BULLETIN 2015 Akita University Outline 2015 Edition [Editing and Publication] Akita University Public Relations Office 1-1 Tegata Gakuen-machi, Akita City 010-8502 Japan TEL: 018-889-3019 FAX: 018-889-3242 E-mail: [email protected] http://www.akita-u.ac.jp 01 Message from the President 02 Mid-term Objective and Plan Education, Research, Contributions to Society, International Exchange 05 Distinguished Education and Research 06 Contributions to Society 08 International Exchange Faculty, Graduate School 11 Faculty of International Resource Sciences 12 Faculty of Education and Human Studies 13 Faculty of Medicine 14 Faculty of Engineering Science 15 Graduate School of Education Graduate School of Medicine Graduate School of Engineering and Resource Science University Facilities 17 University Library 18 University Hospital AKITA 20 Mining Museum 21 Affiliated Schools and Facilities for Education and Research UNIVERSITY 22 University Common Use Facilities for Education and Research 23 Center for Education and Research/Technological Organization 2015 24 Welfare Facilities/Sports Facilities 25 Tokyo Satellite Office/Yokote Branch School, GENERAL INFORMATION BULLETIN Kita Akita Branch School, Oga Namahage Branch School 26 Information Center CONTENTS INFORMATION 28 Historical Sketch 31 Academic Organization 32 Student Quota, Current Student Data 33 New Student Application and Entrant -
Icmr 2005 Akita
ICMR 2005 AKITA Akita Map Around the Site University Tegata Tunnel Senshu Park Medical lnstitute Pref. Hall Pref.Art Museum Pond JR Akita Station Bus Stop Akita Castle Hotel Atorion Akita View Hotel N ICMR2005 Conference Alve Site Akita Shinkansen Akita 1 10000 Time Schedule of ICMR2005 October 20 (Thursday) Plenary Session Main Room 8:00- Registration 9:10- 9:25 Opening Ceremony 9:30-11:45 Session 1 9:30-10:05 PL-1. Sung-Kee Chung, Pohang University of Science and Technology (Korea) 10:05-10:40 PL-2. Robert M. Corn, University of California (U.S.A.) 10:40-11:15 PL-3. Tomokazu Matsue, Tohoku University (Japan) 11:15-11:45 PL-4. Yoshinobu Baba, Nagoya University (Japan) Lunch Break (11:45-13:00) 13:00-14:45 Session 2 13:00-13:35 PL-5. Akira Harada, Osaka University (Japan) 13:35-14:10 PL-6. Kwan-Young Lee, Korea University (Korea) 14:10-14:45 PL-7. Reiner Kirchheim, Universi¨tat G¨ottingen (Germany) 15:00-16:45 Session 3 15:00-15:35 PL-8. Satoshi Matsumoto, Akita Prefectural University (Japan) 15:35-16:10 PL-9. Antonio Rubio, Technical University of Catalonia (Spain) 16:10-16:45 PL-10. Akira Tonomura, Hitachi, Ltd. (Japan) 17:30-19:30 Conference Party October 21(Friday) Keynote Session Room A Room B 8:00- Registration 8:00- Registration 9:10-10:30 Session A1 9:10-10:30 Session B1 New Materials for Life Science New Recycring System and Environmental Al-1, Al-2, Al-3, Al-4 Science and Technology-I B1-1, B1-2, B1-3, B1-4 10:40-12:00 Session A2 10:40-12:00 Session B2 Construction Materials for Sustainable New Recycring System and Environmental -
28Th Asian and Pacific Conference of Correctional Administrators
28th Asian and Pacific Conference of Correctional Administrators 23rd to 28th November 2008 Langkawi, Malaysia By Neil Morgan and Irene Morgan (in collaboration with the Malaysian Prison Department and the APCCA Secretariat) CONTENTS Page HISTORY AND ROLE OF APCCA 1 OPENING CEREMONY AND OFFICIAL SPEECHES 5 Agenda Item 1 National Report on Contemporary Issues in 10 Corrections Agenda Item 2 Balancing Prison Management with the Increased 22 Security of Corrections by External Bodies Agenda Item 3 Best Practices in Rehabilitation for Women and 31 Other Special Groups of Prisoners Agenda Item 4 Engaging Families and Communities in the 44 Rehabilitation Process (including Restorative Justice approaches) Specialist Workshop 1 Developing Correctional Standards that Reflect 55 International and Regional Best Practice and Measuring Performance Specialist Workshop 2 Designing Prisons to Promote Effective 61 Rehabilitation and Environmental Sustainability Specialist Workshop 3 Building Capacity through the Recruitment, 68 Management and Retention of Talent and Through Good Succession Planning CONFERENCE BUSINESS 77 CLOSING CEREMONY 87 Photos 95 Appendix A List of Participants 105 Appendix B Correctional Statistics for Asia and the Pacific 2008 144 Appendix C Conference Program 2008 154 Appendix D APCCA Discussion Guide 2008 158 Appendix E List of Agenda Items at APCCA (1980 – 2008) 174 Appendix F List of Specialist Workshops at 21st to 28th APCCA 178 Appendix G Report on Administration of APCCA Fund 179 Appendix H APCCA Secretariat Report 186 Appendix -
Effects of Recombinant Thrombomodulin on Long-Term
Transplant Immunology 57 (2019) 101247 Contents lists available at ScienceDirect Transplant Immunology journal homepage: www.elsevier.com/locate/trim Short communication Effects of recombinant thrombomodulin on long-term prognosis after allogeneic hematopoietic stem cell transplantation T ⁎ Shosaku Nomuraa, , Akiko Konishia, Yukie Tsubokuraa, Yoshiko Azumaa, Masaaki Hottaa, Hideaki Yoshimuraa, Takahisa Nakanishia, Shinya Fujitaa, Atsushi Satakea, Yuta Katayamab, Shuichi Ohtac, Kunio Hayashid, Kazuyoshi Ishiia, Tomoki Itoa a Kansai Medical University, Japan b Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan c Sapporo-Hokuyu Hospital, Japan d Meiwa Hospital, Japan ARTICLE INFO ABSTRACT Keywords: We investigated the effects of early recombinant thrombomodulin (rTM) treatment on long-term prognosis after Hematopoietic stem cell transplantation hematopoietic stem cell transplantation (HSCT). Subjects included 300 patients who underwent allogeneic HSCT Recombinant thrombomodulin (131 in the rTM(+) group and 169 in the rTM(−) group). The control group received heparin or no anti- Cumulative overall survival probability aGVHD coagulation therapy. When we examined patients with confirmed complications (day 1–100), the frequencies of TMA acute graft-versus-host disease (aGVHD) and thrombotic microangiopathy (TMA) were significantly lower in the rTM(+) group, while the frequencies of veno-occlusive disease did not show such differences. rTM adminis- tration was associated with significant differences in the cumulative incidence of aGVHD (any grade and II-IV grades) and TMA. The cumulative overall survival probability was significantly higher in the rTM(+) group (42.3% versus 26.2%, p = .037). Therefore, some causes of a poor prognosis included aGVHD and TMA. The present findings suggest that rTM plays a preventive role in transplant-related complications, such as aGVHD and TMA, after allogeneic HSCT. -
Integrated Report 2020 (For Viewing)
Integrated Report 2020 Tadano Ltd. Ko-34 Shinden-cho, Takamatsu, Kagawa, 761-0185, Japan Phone: +81-87-839-5555 Fax: +81-87-839-5743 URL: www.tadano.com *Data published in this report This report provides financial and product information published in the financial results for fiscal year 2019 (ended March 31, 2020) and all other information current as of October 1, 2020. m010_0390587912012.indd 1-2 2020/12/24 16:40:09 Integrated Report 2020: Greetings from the President Koichi Tadano President & CEO First and foremost, I want to convey my condolences to the families of that change in complex ways. The Tadano Red Arrow (the color of those who have lost their lives to coronavirus disease (COVID-19) and passion) represents self-support efforts, or thinking and focusing on hope for the earliest possible recovery for those suffering from the things we can control ourselves. The Tadano Yellow Arrow (the color disease. I also want to express my sincere gratitude to those who are of gold) represents large-scale investments such as construction of endeavoring to prevent the spread of infections. new plants and M&As. Combining the three Tadano Arrows produces the Tadano Black Arrow (the color of prots). We must continue to With the business objective of implementing our corporate philosophy strive both in good times and bad, and grow while producing results of Sozo (Creation), Hoshi (Contribution) and Kyoryoku (Cooperation), every year. This means that the Red Arrow must always be pointing the Tadano Group stays true to its original missions of “providing up. This is the company that we want to be. -
Efficacy and Long-Term Outcome of Treatment for Pure
Biol Blood Marrow Transplant 19 (2013) 1026e1032 Efficacy and Long-Term Outcome of Treatment for Pure Red Cell Aplasia after Allogeneic Stem Cell Transplantation from ASBMT American Society for Blood Major ABO-Incompatible Donors and Marrow Transplantation Makoto Hirokawa 1,*, Takahiro Fukuda 2, Kazuteru Ohashi 3, Michihiro Hidaka 4, Tatsuo Ichinohe 5, Koji Iwato 6, Heiwa Kanamori 7, Makoto Murata 8, Toru Sakura 9, Masahiro Imamura 10, Soichi Adachi 10, Ritsuro Suzuki 10, Yasuo Morishima 10, Hisashi Sakamaki 10, for The PRCA Collaborative Study Group 1 Akita University, Akita, Japan 2 National Cancer Center Hospital, Tokyo, Japan 3 Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan 4 National Hospital Organization, Kumamoto Medical Center, Kumamoto, Japan 5 Kyoto University, Kyoto, Japan 6 Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan 7 Kanagawa Cancer Center, Yokohama, Japan 8 Nagoya University Graduate School of Medicine, Nagoya, Japan 9 Saiseikai Maebashi Hospital, Maebashi, Japan 10 Japan Society of Hematopoietic Cell Transplantation, Nagoya, Japan Article history: abstract Received 12 November 2012 No standard of care for pure red cell aplasia (PRCA) after major ABO-incompatible hematopoietic stem cell Accepted 5 April 2013 transplantation (HSCT) has been established. We conducted a retrospective cohort study to learn the efficacy and outcome of treatment for PRCA. One hundred forty-five recipients who showed delayed recovery of Key Words: erythropoiesis and survived >100 days after transplantation without early disease progression were selected Major ABO-mismatched HSCT from 2846 records of major ABO-incompatible transplantation in the registry database in Japan, and detailed PRCA data of 46 recipients were collected.